Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12059544 | 0.97 | GRM2 (0.37) | L3MBTL1HRH3RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6923613 | 0.97 | GRM2 (0.37) | L3MBTL1HRH3RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6922582 | 0.86 | GRM5 (0.47) | L3MBTL1RAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL6922907 | 0.83 | GRM5 (0.45) | GRM5 | |
| SCHEMBL15865811 | 0.83 | GRM5 (0.45) | GRM5 | |
| SCHEMBL6922176 | 0.82 | CYP2C9 (0.38) | HRH3KDM2B | |
| SCHEMBL6922154 | 0.82 | NPC1 (0.39) | L3MBTL1HRH3RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6920698 | 0.80 | ALDH1A1 (0.40) | L3MBTL1RAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL12059605 | 0.79 | KDM2B (0.44) | L3MBTL1HRH3RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6922431 | 0.78 | NPC1 (0.39) | L3MBTL1HRH3RAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | L3MBTL1 3622/4885HRH3 1089/4885RAB9A 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.